Stock Analiz

MRNA vs BIIB stock comparison

Moderna vs. Biogen · data as of November 13, 2026

Moderna (MRNA) has a market value of about $90.4B, Biogen (BIIB) about $37.5B. Over their latest twelve months Moderna had revenue of $2.5B and Biogen $10.3B.

On our five checks Biogen scores higher: 1.8 out of 5 (weak) against 1.0 (weak).

By area, the stronger company is Biogen on value; Biogen on future growth; Biogen on financial health.

Moderna leads on 3 of the compared lines and Biogen on 11.

Side by side

MRNABIIB
Size and price
Market cap$90.4B$37.5B
Share price$223.37$253.40
Score
Overall score (of 5)1.01.8
Value01
Future growth12
Track record11
Financial health24
Shareholder returns11
Valuation
P/E (TTM)—109.2
Forward P/E—17.4
Price / free cash flow—18.1
Price / sales35.83.6
EV / EBITDA—26.7
PEG——
DCF value vs. price—−33%
Business
Revenue$2.5B$10.3B
Net income-$2.8B$348M
Free cash flow-$2.0B$2.1B
Net margin-110.5%3.4%
Gross margin (5-yr avg.)59.9%76.9%
ROIC (5-yr avg.)9.4%9.2%
Growth
Revenue growth (1 yr)-39.9%2.2%
Revenue growth (5 yrs, per year)19.3%-6.0%
EPS growth (5 yrs, per year)—-18.7%
Balance sheet and payouts
Net cash (cash minus debt)$3.9B-$6.1B
Dividend yieldNoneNone
Shareholder yield0.0%0.0%
Analysts
Upside to average target−29%+6%
Consensus ratingHoldBuy

Highlighted = the better figure on that line. Revenue, net income and free cash flow: MRNA TTM to September 30, 2026, BIIB TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Moderna or Biogen?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Biogen scores 1.8 out of 5 and Moderna 1.0; the table shows where each one is stronger.

Which grows faster, Moderna or Biogen?

Over five years Moderna grew revenue about 19.3% a year and Biogen about -6.0% a year.

Full Moderna analysis → Full Biogen analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.